LXFR vs TROX: stock comparison and AI forecast
Luxfer Holdings Plc (LXFR) and Tronox Holdings Plc (TROX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
LXFR Luxfer Holdings Plc
- Price
- $17.22 +13.9% · 6M
- Market Cap
- $461M
- P/E Ratio
- 82.0x
- Size
- small-cap
- AI Forecast
TROX Tronox Holdings Plc
- Price
- $3.46 -65.4% · 6M
- Market Cap
- $553M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- TROX is 1.2 times larger than LXFR by market capitalization ($553M against $461M).
- Over the last six months LXFR returned +13.9% and TROX -65.4%.
- LXFR turns 1.7% of its revenue into net income, against -18.0% for TROX.
- TROX carries 4.10 times debt per unit of equity, against 0.73 times for LXFR.
- TROX yields 7.96% in dividends and LXFR 2.97%.
- Both companies share the SEC industry classification Industrial Inorganic Chemicals.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | LXFR | TROX |
|---|---|---|
| Market Cap | $461M | $553M |
| P/E Ratio | 82.00x | – |
| P/B Ratio | 2.08x | 0.48x |
| Dividend Yield | 2.97% | 7.96% |
| EPS | $0.21 | $-3.51 |
| Book Value/Share | $8.29 | $7.27 |
| Revenue/Share | $13.60 | $19.14 |
| FCF/Share | $0.70 | $-1.00 |
Profitability & Margins
| Metric | LXFR | TROX |
|---|---|---|
| ROE | 2.8% | -47.3% |
| ROA | 1.6% | -9.2% |
| ROIC | 6.5% | -4.3% |
| Gross Margin | 25.1% | 6.2% |
| Operating Margin | 5.4% | -7.2% |
| Net Margin | 1.7% | -18.0% |
| EBT Margin | 4.3% | -14.5% |
| Tax Rate | 40.1% | -25.3% |
Financial Health
| Metric | LXFR | TROX |
|---|---|---|
| Current Ratio | 2.47x | 2.55x |
| Quick Ratio | 1.19x | 0.81x |
| D/E Ratio | 0.73x | 4.10x |
| Financial Leverage | 1.73x | 5.12x |
| Interest Coverage | 5.6x | -0.2x |
| Working Capital | $114M | $1.30B |
Cash Flow
| Metric | LXFR | TROX |
|---|---|---|
| Operating Cash Flow | $30M | $101M |
| Free Cash Flow | $19M | -$159M |
| Capital Spending | -$11M | -$260M |
| OCF Growth YoY | -32.1% | -38.8% |
| FCF Growth YoY | -48.5% | – |
| FCF/Sales | 5.1% | -5.2% |
| CapEx/Sales | 3.0% | 8.5% |
Operational Efficiency
| Metric | LXFR | TROX |
|---|---|---|
| Asset Turnover | 0.95x | 0.51x |
| Receivables Turnover | 5.8x | 8.4x |
| Inventory Turnover | 2.8x | – |
| Fixed Assets Turnover | 5.9x | 1.5x |
| Days Sales Outstanding | 63 days | 43 days |
| Days Inventory | 133 days | – |
| Payables Period | 29 days | – |
| Cash Conversion Cycle | 166 days | – |
Income Statement
| Metric | LXFR | TROX |
|---|---|---|
| Total Revenue | $364M | $3.06B |
| Operating Income | $20M | -$219M |
| Net Income | $6M | -$549M |
| R&D Expense | $6M | – |
| SG&A Expense | $49M | $287M |
| Cost of Goods Sold | $272M | – |
Dividend & Shareholder Information
| Metric | LXFR | TROX |
|---|---|---|
| Dividends Per Share | $0.51 | $0.28 |
| Payout Ratio | 242.9% | – |
| Shares Outstanding | 27M | 160M |
| Net Income Growth | -56.6% | – |
| EPS Growth | -32.3% | – |
LXFR vs TROX: stock comparison and AI forecast
Which is bigger, LXFR or TROX?
TROX is 1.2 times larger than LXFR by market capitalization ($553M against $461M).
Which stock performed better over the last six months, LXFR or TROX?
Over the last six months LXFR returned +13.9% and TROX -65.4%.
Which one does Intratio's AI model rank higher, LXFR or TROX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.